February 3, 2005 -- In a down-all-day affair, biotech moved lower on Thursday, although it managed to erase some of its losses in a last-minute surge. At the close, the Centient Biotech 200 was down 13.35 points to close at 3393.63, a .39% slide. Cyberonics gained a huge 42% after receiving an FDA approvable letter, which was a suprise, Myogen lost 21% after stretching out a clinical trial, Icagen priced its IPO below expectations and then sold off in open market trading, MedImmune rose even though it guided analysts lower for next year, Mylan sank after missing estimates, and CuraGen gave up some value after announcing its loss. We give the details...
